Mini Diamonds secures Rs 17.17 crore export order for lab-grown diamonds from Singapore
Mini Diamonds (India) Ltd (BSE: 523373) announced on July 15 that it has received an export order worth USD 2 million (approx. ₹17.17 crore) for supplying lab-grown polished diamonds to Dia-Globe Singapore PTE Ltd.
According to the company's exchange filing, the export order is to be executed within 60 days, with payment expected within 150 days of order completion. This development aligns with Mini Diamonds' strategy to expand its international business portfolio and strengthen its presence in global markets.
Commenting on the milestone, Shri Upendra N. Shah, Chairman & Managing Director, said:
'We are encouraged by the sustained traction and growing acceptance of lab-grown diamonds in global markets. This order reflects the trust our clients place in us and aligns with our objective of scaling exports while diversifying our customer base.'
The company highlighted that growing global demand for lab-grown diamonds is creating significant opportunities for Indian manufacturers. Mini Diamonds expects this order to contribute meaningfully to its sales growth in the coming quarters.
As per disclosures, there is no related-party transaction involved in this order, and the promoter group has no interest in the client awarding the contract.
About Mini Diamonds
Established in 1987, Mini Diamonds is engaged in manufacturing, processing, and exporting cut and polished diamonds and diamond jewellery. It operates a state-of-the-art facility in Mumbai, equipped with modern technologies for diamond cutting, polishing, and jewellery making. The company focuses on delivering high-quality, cost-effective lab-grown diamonds to both Indian and international markets.
Ahmedabad Plane Crash
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
a few seconds ago
- Business Upturn
Top Q1 results today, August 6: Bajaj Auto, Hero MotoCorp, Trent, Divi's Laboratories, BHEL and more to announce earnings
A busy earnings day lies ahead on Wednesday, August 6, 2025, as several Indian companies are set to report their financial results for the quarter ended June 2025 (Q1 FY26). Among the key names to watch are Bajaj Auto, Hero MotoCorp, and Trent, which operates the popular fashion retail chain Zudio. Pharma player Divi's Laboratories, financial services firm Bajaj Holdings & Investment, and adhesives major Pidilite Industries are also on the list. Other companies scheduled to release Q1 earnings include Power Finance Corporation (PFC), Bharat Heavy Electricals Ltd (BHEL), Fortis Healthcare, and Raymond Ltd. Here is the full list of companies expected to announce their Q1 FY26 results on August 6: Bajaj Auto Ltd Divis Laboratories Ltd Trent Ltd Hero MotoCorp Ltd Bajaj Holdings & Investment Ltd Pidilite Industries Ltd Power Finance Corporation Ltd Bharat Heavy Electricals Ltd Fortis Healthcare Ltd UNO Minda Ltd Bharat Forge Ltd Housing & Urban Development Corporation Ltd (HUDCO) KPR Mill Ltd Blue Star Ltd Jindal Stainless Ltd Krishna Institute of Medical Sciences Ltd Bayer CropScience Ltd SKF India Ltd Jyoti CNC Automation Ltd EID Parry (India) Ltd Godrej Agrovet Ltd Kirloskar Oil Engines Ltd RITES Ltd Ircon International Ltd Sundaram Finance Holdings Ltd PVR INOX Ltd Cera Sanitaryware Ltd Gujarat Narmada Valley Fertilizers & Chemicals Ltd (GNFC) TD Power Systems Ltd Raymond Lifestyle Ltd Electrosteel Castings Ltd Welspun Enterprises Ltd VIP Industries Ltd Datamatics Global Services Ltd Rain Industries Ltd VRL Logistics Ltd Hawkins Cooker Ltd Bannariamman Sugars Ltd NIIT Learning Systems Ltd Gopal Snacks Ltd Raymond Ltd Sundaram-Clayton Ltd Indraprastha Medical Corporation Ltd Harsha Engineers International Ltd Prince Pipes & Fittings Ltd Lumax Industries Ltd Balmer Lawrie & Co Ltd Morepen Laboratories Ltd Protean eGov Technologies Ltd Windsor Machines Ltd Tasty Bite Eatables Ltd Hinduja Global Solutions Ltd Ravindra Energy Ltd Afcom Holdings Ltd Sula Vineyards Ltd Sanghvi Movers Ltd Shipping Corporation of India Land and Assets Ltd Tinna Rubber and Infrastructure Ltd MM Forgings Ltd GPT Healthcare Ltd Tribhovandas Bhimji Zaveri Ltd Peninsula Land Ltd Linc Ltd Monte Carlo Fashions Ltd Ahmedabad Plane Crash Bajaj AutoBHELDivi's LaboratoriesHero MotocorpTrent Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
2 hours ago
- Business Upturn
Nxera Launches Broad Proprietary Pipeline Targeting Obesity and Chronic Weight Management
Pipeline led by a new proprietary oral small molecule GLP-1 agonist and six additional innovative programs targeting the GIP, Amylin and Apelin receptors, aiming to transform treatment landscape Designed to address emerging areas of patient need, including long-term weight management, co-morbid metabolic disorders, and muscle preservation during weight loss Tokyo, Japan and Cambridge, UK, 6 August 2025 – Nxera Pharma Co., Ltd. ('Nxera'; TSE: 4565) a technology-powered biopharmaceutical company, today announces the launch of a broad new pipeline strategically focused on advancing next-generation therapies for obesity and associated metabolic disorders. Independent to the productive drug discovery collaborations with Pfizer and Eli Lilly, Nxera has established, expanded and accelerated drug discovery efforts of its own proprietary pipeline across a broad range of validated GPCR targets in these major disorders. Chris Cargill, President and CEO of Nxera, commented: 'Nxera scientists were among the pioneers in elucidating the structure of the GLP-1 receptor and other key receptors being targeted, giving us a clear advantage in developing potentially best-in-class next generation drug candidates. For the past 12 months, Nxera scientists have been advancing a broad metabolic disease pipeline to capitalize independently on our differentiated science. Today, we reveal the addition of these programs to our discovery portfolio, and are confident in achieving significant progress over the mid-term, delivering clear value for shareholders and patients in the rapidly expanding obesity market, projected to exceed US$100 billion annually in global sales.' Central to Nxera's pipeline is its new, wholly owned oral small molecule GLP-1 agonist program, focussed on differentiated chemistry, which is distinct, independent and developed separately from Pfizer's PF-06954522, allowing Nxera full control to drive rapid progress. Complementing this program, Nxera is simultaneously accelerating the advancement of an additional six established GPCR-targeted programs focused on obesity and chronic weight management: Three small molecule agonist programs (GIP, Apelin, Amylin) One small molecule antagonist program (GIP) Two long-acting programs (targets undisclosed) Nxera's pipeline leverages its proprietary NxWave™ GPCR-focused structure-based design platform to rapidly identify unique, highly differentiated lead molecules with novel chemistry. This process utilizes Nxera's NxHit proprietary small molecule libraries and NxStaR proteins for DNA encoded library (DEL) screening, distinguishing these candidates from others currently in discovery and clinical development globally. Nxera's focused approach is designed to deliver highly effective therapies addressing critical patient needs: Long-term weight maintenance: Convenient, scalable oral therapies for sustained weight loss. Convenient, scalable oral therapies for sustained weight loss. Targeting key obesity-related co-morbidities: Enhanced outcomes in cardiovascular, renal, and liver diseases, with new therapeutic indications emerging continuously. Enhanced outcomes in cardiovascular, renal, and liver diseases, with new therapeutic indications emerging continuously. Reducing side effects and broadening out to difficult to treat populations: Targeted treatments for elderly, post-menopausal, and sarcopenic populations. Backed by an expert team with deep experience in GPCR drug discovery, Nxera is strategically positioned to be a leader in developing the next generation of best-in-class obesity and metabolic therapies. Nxera maintains its strong commitment to other key therapeutic areas including neurology, gastroenterology, and immunology, continuing to leverage the NxWave™ platform's proven capabilities in these domains. Separately, Nxera notes that Pfizer yesterday discontinued development of its Phase 1 candidate PF-06954522, a separate small molecule GLP-1 agonist, which was discovered under a strategic drug discovery collaboration with Nxera. This discontinuation by Pfizer was due to a portfolio decision and not because of any adverse safety findings. Nxera intends to enter discussions with Pfizer regarding potential opportunities to advance GLP-1 molecules discovered by Pfizer under the collaboration. Nxera will announce its earnings results and present operational highlights for Q2 2025 on Friday, 8 August 2025. –END– About Nxera Pharma Nxera Pharma is a technology powered biopharma company in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. We have built an agile, new-generation commercial business in Japan to develop and commercialize innovative medicines, including several launched products, to address this high value, large and growing market and those in the broader APAC region. Behind that, and powered by our unique NxWave™ discovery platform, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline of potentially first- and best-in-class candidates is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across obesity and metabolic disorders, neurology/neuropsychiatry and immunology and inflammation. Nxera employs approximately 400 talented people at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565). For more information, please visit LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma Enquiries: Nxera – Media and Investor RelationsShinya Tsuzuki, VP, Head of Investor RelationsShinichiro Nishishita, VP Investor Relations, Head of Regulatory DisclosuresMaya Bennison, Communications Manager +81 (0)3 5962 5718 | +44 (0)1223 949390 |[email protected]
Business Upturn
2 hours ago
- Business Upturn
Nonwoven Fabrics Market worth $72.21 billion by 2030, at a CAGR of 5.7%, says MarketsandMarkets™
Delray Beach, FL, Aug. 05, 2025 (GLOBE NEWSWIRE) — The Nonwoven Fabrics Market is anticipated to grow from USD 54.73 billion in 2025 to USD 72.21 billion in 2030, at a CAGR of 5.7%, as per the recent study by MarketsandMarkets™. The nonwoven fabric market is experiencing robust growth, driven by the escalating demand for sanitary, reliable, and high-performance materials across various sectors, including automotive, filtration, medical, and hygiene. Nonwoven materials are characterized by their lightweight composition, superior absorbency, breathability, and cost-effectiveness, making them ideally suited for protective and disposable applications. Their effectiveness, zero maintenance requirements, and consistent quality address the evolving needs of both consumers and industry professionals. These factors contribute to the success of nonwovens as a preferred alternative for manufacturers seeking high-performance, long-lasting, and contamination-free solutions, ranging from automotive insulation to surgical masks. The increasing emphasis on sustainability is catalyzing the advancement of biodegradable and eco-friendly nonwoven fabrics, fundamentally transforming product manufacturing across the hygiene, medical, and packaging sectors. These sustainable nonwovens are produced from materials such as polylactic acid (PLA), bamboo fibers, and other natural or recycled resources. They deliver superior durability, lightweight characteristics, and skin compatibility while significantly minimizing environmental impact. The biodegradable wipes and packaging solutions market has gained considerable traction in daily applications. Leading companies, including Freudenberg Group and Suominen Corporation, are at the forefront of providing sustainable nonwovens that align with global objectives for waste reduction and the promotion of a circular economy. Download PDF Brochure: Browse in-depth TOC on 'Nonwoven Fabrics Market' 383 – Market Data Tables 57 – Figures 320 – Pages List of Key Players in Nonwoven Fabrics Market: Berry Global Inc. (US) Freudenberg Group (Germany) Ahlstrom (Finland) Kimberly-Clark Worldwide, Inc. (US) Fitesa S.A. and Affiliates (Brazil) DuPont (US) Toray Industries, Inc. (Japan) Alkegen (US) Avgol Industries 1953 Ltd (Israel) Zhejiang Kingsafe Hygiene Material Technology Co.,Ltd (China) Suominen Corporation (Finland) Johns Manville (US) Drivers, Opportunities and Challenges in Nonwoven Fabrics Market: Drivers: Surging demand in hygiene and medical applications Restraint: Regulatory pressures restricting use of plastic-based nonwovens Opportunity: Growing demand for advanced filtration in air and water purification applications Challenge: Requirement for high investments in recycling technology Get Sample Pages: Key Findings of the Study: Dry laid segment accounted for second-largest share of nonwoven fabric market in 2024 Building & construction segment accounted for second-largest share of nonwoven fabrics market in 2024 North America held second-largest share of nonwoven fabrics market in 2024 By technology, the spunbond segment holds the largest market share due to its efficiency, cost-effectiveness, and versatility across various applications. Spunbond technology facilitates the continuous production of consistent, durable, and lightweight fabrics, making it ideal for use in hygienic products, medical and healthcare supplies, agricultural coverings, and packaging solutions. The spunbond process is characterized by rapid production capabilities, minimal waste generation, and the adaptability to integrate biodegradable polymers. As demand for disposable and sustainable nonwoven products continues to rise, manufacturers are increasingly investing in upgraded spunbond production lines, utilizing bio-based raw materials, and developing multi-layer structures to enhance performance. Based on end-use industry, hygiene is currently the fastest-growing segment in the market, driven by an escalating demand for high-absorbency, skin-friendly, and disposable materials essential to the hygiene industry. Nonwoven fabrics are particularly well-suited for applications in this sector, including baby diapers, feminine hygiene products, adult incontinence solutions, and personal wipes. Their attributes, such as breathability, softness, and superior fluid management capabilities, make them ideal for these products. Nonwoven fabrics deliver the necessary comfort and performance and adhere to stringent hygiene and safety standards. Get Customization on this Report: In 2024, North America emerged as the second-largest market for nonwoven fabrics, driven primarily by robust demand from the healthcare, hygiene, and automotive sectors. The region boasts a well-established manufacturing infrastructure and leads in technological advancements in nonwoven production. Furthermore, it adheres to stringent regulatory standards that promote the creation of high-performance and sustainable nonwoven products. North America offers multiple entry points for businesses, underpinned by ongoing investments in product development and capacity expansion from key players in the nonwoven industry. The heightened consumer focus on hygiene—exacerbated by the COVID-19 pandemic—has catalyzed increased investment and adoption of single-use, disposable nonwovens across various applications. The US market for nonwoven fabrics is experiencing steady growth, driven by strong demand across the hygiene, medical, filtration, and automotive industries. Key factors contributing to this expansion include advancements in nonwoven technology, a preference for lightweight and high-performance materials, and an increased reliance on disposable and contamination-free products. The presence of leading manufacturers and a well-established industrial base further drives this market. Additionally, high investments in healthcare infrastructure and bioproducts production are facilitating broader acceptance of nonwoven fabrics across diverse applications. The use of automation and the Internet of Things (IoT) presents substantial growth prospects for the nonwoven fabrics market by enhancing efficiency, precision, and sustainability across various sectors. Modern nonwoven production systems are evolving into more intelligent frameworks, characterized by real-time monitoring and predictive maintenance, significantly decreasing reliance on continuous human oversight. IoT sensors and AI-driven tools facilitate the early detection of issues such as material defects, machine deterioration, and production inefficiencies, enabling prompt interventions and minimizing downtime. Manufacturers can capitalize on these advancements by providing digitally integrated nonwoven solutions, particularly for critical applications, including medical products, filtration systems, and hygiene products. Berry Global Inc. (US) is a leading manufacturer and supplier of innovative, environmentally friendly packaging solutions and engineered materials, serving a range of markets, including the healthcare, hygiene, food and beverage, beauty and personal care, construction, filtration, homecare, and specialty sectors. The company's operations are divided into four reporting segments: Consumer Packaging International, Consumer Packaging North America, Flexibles, and Health, Hygiene & Specialties Freudenberg Group (Germany) is a worldwide technology company committed to providing intelligent solutions that drive customer success and foster sustainable development in various industries. The group provides a broad portfolio of products, including seals and nonwovens, consumer products, lubricants, and IT services. The company's operations are structured into several business segments: Seals and Vibration Control Technology, Technical Textiles and Filtration, Cleaning Technologies and Products, and Specialties, each supported by specialist business groups. Browse Adjacent Markets Yarns, Fabric and Textile Market Research Reports & Consulting Related Reports: Polyethylene Furanoate (PEF) Market Data Center Cooling Market Elevators & Escalators Market Glass Substrate Market Centrifuge Market Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
